WO1993002558A1 - Method and formulation for reducing microbial populations - Google Patents
Method and formulation for reducing microbial populations Download PDFInfo
- Publication number
- WO1993002558A1 WO1993002558A1 PCT/US1991/003796 US9103796W WO9302558A1 WO 1993002558 A1 WO1993002558 A1 WO 1993002558A1 US 9103796 W US9103796 W US 9103796W WO 9302558 A1 WO9302558 A1 WO 9302558A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- lactobacillus
- whey
- sugar
- oral administration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000009472 formulation Methods 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000000813 microbial effect Effects 0.000 title description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 56
- 239000005862 Whey Substances 0.000 claims abstract description 49
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 49
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 49
- 241000186660 Lactobacillus Species 0.000 claims abstract description 45
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 40
- 235000000346 sugar Nutrition 0.000 claims abstract description 30
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 24
- 241000186712 Lactobacillus animalis Species 0.000 claims abstract description 15
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 15
- 244000144977 poultry Species 0.000 claims description 26
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 20
- 239000008101 lactose Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 abstract description 12
- 235000013594 poultry meat Nutrition 0.000 description 24
- 239000000654 additive Substances 0.000 description 16
- 230000000996 additive effect Effects 0.000 description 16
- 241000271566 Aves Species 0.000 description 15
- 244000005700 microbiome Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 241000286209 Phasianidae Species 0.000 description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 7
- 241001135257 Salmonella enterica subsp. enterica serovar Senftenberg Species 0.000 description 7
- 210000004534 cecum Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000288147 Meleagris gallopavo Species 0.000 description 5
- 241000736262 Microbiota Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 244000180419 Brassica nigra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010039737 Scratch Diseases 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 235000019755 Starter Diet Nutrition 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000002368 bacteriocinic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 231100000586 procarcinogen Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000006054 starter diet Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
- A23K10/28—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin from waste dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Definitions
- This invention relates generally to a method and composition for reducing microbial populations, and more particularly, to a composition containing Lactobacillus and a carbohydrate for use in decreasing the numbers of pathogens in the gastrointestinal tract which do not utilize lactose, such as Salmonella.
- Lactobacillus reuteri, L. animalis. and L. salivarius are naturally occurring microorganisms in the GI tract of animals including domestic avian species (Sarra, et al., 1985, System Appl. Microbiol 6:86-89). This paper and all other papers cited herein are hereby incorporated herein by reference.
- Lactobacillus reuteri is a symbiotic resident of the gastrointestinal (GI) tracts of humans, swine and other animals.
- the neotype strain of L. reuteri is DSM 20016 (ATCC No. 53609).
- This strain and strain 1063 (ATCC No. 53608), discussed in the co-pending application, are available to the public at the American Type Culture Collection (Rockville, MD) having been deposited therein April 17, 1987.
- the GI tract of animals is a complex ecosystem harboring an estimated 300-500 species of microorganisms, known collectively as the indigenous microbiota or microflora.
- enteric diseases Under certain conditions some members of the indigenous microbiota can become opportunistic pathogens causing a variety of enteric diseases. More often, however, pathogens gain access to the GI tract as contaminants in food or water. Notable among the latter . are a number of bacterial genera including Escherichia. Salmonella, Shi ⁇ ella, ⁇ ersina. Vibrio, Campylobacter and Clostridiurrt- as well as viruses (e.g., roto-, astro- and ciliciviruses) and intestinal parasites (e.g., Giardia and Entamoeba species) . Acute and chronic enteric diseases caused by these and other microorganisms occur worldwide causing considerable human misery and loss of economically important animals. Certain microbial activities have also been associated with production of mutagens within the GI trac .
- the indigenous microbiota can provide their hosts with an assortment of benefits including among others protection against enteric pathogens (a process known as colonization resistance or competitive exclusion) , stimulation of normal development and function of the GI mucosa, production of various vitamins and other nutrients, and re-metabolism of the host's abundant endogenous mucosal tissue.
- Lactobacillus plantarum strains are grown commercially in large amounts and used as starter cultures for the commercial preservation of a variety of human foods (meats, vegetables, and dairy products) and animal foods (silage). Lactobacillus acidophilus strains are grown commercially in large amounts to be added to human (e.g., milk) or animal (feedstuffs) foods as a means of introducing these bacteria into the GI tract where they can exert beneficial effects. Although these bacteria are likely to be already present in the GI tract their numbers may vary widely from individual to individual, and therefore beneficial effects of these bacteria may not be present in persons deficient in these bacteria.
- Lactobacillus reuteri was previously found to be recoverable from the stools of piglets after the piglets had been fed large quantities of the cells (co-pending application) . It was hypothesized in the co-pending application that such cells could be used, possibly in conjunction with glycerol, as a growth and health aid for these animals. Evidence has been obtained (and presented below) that L.reuteri may be administered to poultry as a means of competitively excluding salmonellae.
- the invention is for a formulated product that may be used as an animal feed additive and that includes isolated and identified pure culture(s) of naturally occurring gastrointestinalmicroorganisms, for example, Lactobacillus reuteri, L. animalis, and/or L. salivarius.
- the formulated product also includes a sugar source.
- the invention also includes a method of feeding the formulation to animals.
- the sugar source is whey, when animals which do not metabolize lactose such as chickens are used, because whey contains the sugar lactose and is an easily obtainable and voluminous waste product.
- the formulation of the invention when fed to animals provides a means to decrease populations of undesirable gastrointestinal microbes and results in increased weight gain of the animals, especially under the less than optimum growth conditions normally present in commercial livestock environments.
- group animals of a particular species or group of species which share in common a tendency to have a similar gastrointestinal Lactobacillus flora and a similar inability to metabolize a sugar which is metabolizable by the Lactobacillus flora.
- the formulation discussed in detail herein has been devised for poultry but is adaptable to other animals, and includes a source of lactose which is not metabolizable by poultry.
- control weights no whey, no L. reuteri at each weight day were made equal to 100%.
- the invented formulation may be used as a food or food additive mixture for animals grown commericially, such as poultry. It provides a product that results in rapid weight gain for growing animals, and decreases the number of pathogenic microorganisms in the gastrointestinal tract, thereby resulting in increased productivity and decreased animal mortality.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A formulation including one or more pure cultures of Lactobacillus, such as L.reuteri, L.animalis and L.salivarius and a sugar source, such as whey and a method of feeding animals which utilizes the formulation to be ingested by the animals with their normal food.
Description
METHOD AND FORMULATION FOR REDUCING MICROBIAL POPULATIONS
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates generally to a method and composition for reducing microbial populations, and more particularly, to a composition containing Lactobacillus and a carbohydrate for use in decreasing the numbers of pathogens in the gastrointestinal tract which do not utilize lactose, such as Salmonella.
Description of the Related Art
Lactobacillus reuteri, L. animalis. and L. salivarius are naturally occurring microorganisms in the GI tract of animals including domestic avian species (Sarra, et al., 1985, System Appl. Microbiol 6:86-89). This paper and all other papers cited herein are hereby incorporated herein by reference.
As disclosed in co-pending application Serial No. 07/268,361 filed September 19, 1988, the disclosure of which is incorporated herein, Lactobacillus reuteri is a symbiotic resident of the gastrointestinal (GI) tracts of humans, swine and other animals. The neotype strain of L. reuteri is DSM 20016 (ATCC No. 53609). This strain and strain 1063 (ATCC No. 53608), discussed in the co-pending application, are available to the public at the American Type Culture Collection (Rockville, MD) having been deposited therein April 17, 1987. The GI tract of animals is a complex ecosystem harboring an estimated 300-500
species of microorganisms, known collectively as the indigenous microbiota or microflora. Despite over 100 years of intensive research in the field of intestinal microbiology much remains to be learned about these microorganisms, the complex interrelationships that exist between the different species, and the nature of the symbiotic relationships existent between the microbiota and their host.
Under certain conditions some members of the indigenous microbiota can become opportunistic pathogens causing a variety of enteric diseases. More often, however, pathogens gain access to the GI tract as contaminants in food or water. Notable among the latter . are a number of bacterial genera including Escherichia. Salmonella, Shiσella, ϊersina. Vibrio, Campylobacter and Clostridiurrt- as well as viruses (e.g., roto-, astro- and ciliciviruses) and intestinal parasites (e.g., Giardia and Entamoeba species) . Acute and chronic enteric diseases caused by these and other microorganisms occur worldwide causing considerable human misery and loss of economically important animals. Certain microbial activities have also been associated with production of mutagens within the GI trac .
It is also known that other members of the indigenous microbiota exist in a symbiotic or synergistic relationship with their host contributing in many positive ways to the host's general health and well-being. It is well-known that germ-free animals are very susceptible to pathogens
and have poorly developed GI tracts. In return for the nutrient-rich and stable ecosystem provided for them, the indigenous microbiota can provide their hosts with an assortment of benefits including among others protection against enteric pathogens (a process known as colonization resistance or competitive exclusion) , stimulation of normal development and function of the GI mucosa, production of various vitamins and other nutrients, and re-metabolism of the host's abundant endogenous mucosal tissue. It has been reported on numerous occasions that the enteric lactobacilli (i.e., bacteria belonging to the genus Lactobacillus which reside in the GI tract and which include a large number of nonpathogenic, non-toxic bacteria) play an important role in the health and well- being of their human and animal hosts. Included in this role is their ability to regulate conditions in the GI tract so that the different populations of microorganisms in this system are kept in a healthy balanced state (Fuller, 1977, Br. Poultry Sci. 18:85-94). Certain Lactobacillus species in fact are added to human and animal foodstuffs either to preserve them, enhance their flavors and/or exert other beneficial effects in the GI tract. Lactobacillus plantarum strains, for example, are grown commercially in large amounts and used as starter cultures for the commercial preservation of a variety of human foods (meats, vegetables, and dairy products) and animal foods (silage). Lactobacillus acidophilus strains are grown commercially in large amounts to be added to human (e.g.,
milk) or animal (feedstuffs) foods as a means of introducing these bacteria into the GI tract where they can exert beneficial effects. Although these bacteria are likely to be already present in the GI tract their numbers may vary widely from individual to individual, and therefore beneficial effects of these bacteria may not be present in persons deficient in these bacteria. Reports on the beneficial effects resulting from the oral administration of live Lactobacillus cultures have increased in recent years with findings that dietary Lactobacillus therapy affords protection from colon cancer for human populations on western diets, reduces the incidence of experimentally induced large bowel tumors in rats, reduces the fecal concentration of bacterial enzymes known to catalyze the conversion of procarcinogens to proximal carcinogens in humans, and reduces the serum cholesterol levels in swine.
Themetabolic endproducts ofLactobacillus metabolism, such as acetic acid, lactic acid and hydrogen peroxide, are well-known for their antimicrobial activities. They are believed to play a significant role in maintaining proper conditions within the GI tract. Some lactobacilli produce bacteriocins or bacteriocin-like proteins which also exhibit bacteriocidal activity toward other members of that species or closely related species. Reports have appeared concerning low molecular weight, antimicrobial substances produced by lactobacilli. With the exception of reuterin which is produced by Lactobacillus reuteri (copending
application) none of these low molecular weight substances has been identified and these reports have not been confirmed. In fact, some of these substances have proven to be none other than lactic acid, acetic acid or hydrogen peroxide.
Several studies have been conducted to determine the effect of lactobacilli on the performance of domestic avian species. Some of these studies indicate that dosing broilers with L. acidophilus improved their growth (Tortuero, 1973, Poultry Sci. 52:197-203, and Dilworth and Day, 1978, Poultry Sci. 57:1101). An increase in egg production as a result of addition of lactobacilli to laying hens feed has also been reported (Hargis and Creger, 1978, Poultry Sci. 57:1103). Improvement of young turkeys' body weight and feed efficiency was obtained with a Lactobacillus product added to the feed (Francis et al., 1978, Poultry Sci. 57:1687- 1689). Similar effects were reported (Potter et al., 1986, Poultry Sci. (Suppl. 1) 65:107) when L. acidophilus in combination with varying protein levels was fed to turkeys up to 12 weeks of age, but no difference with the controls was observed at 16 weeks. Dosage of 107 colony forming units (CFU) and higher depressed chick growth (Watkins and Kratzer, 1982, Poultry Sci. 61:1565, and, 1984, Poultry Sci. 63:1671-1673).
Other strains of lactobacilli did not stimulate broilers weight gain (Watkins and Kratzer, 1984), and did not stimulate egg production (Goodling et al., 1987,
Poultry Sci. 66:480-485). Damron et al. (1981, Poultry Sci. 60:1350-1351) did not find any beneficial effect of L. acidophilus and other lactobacilli cultures in turkey breeder hens. Nurmi and Rantala (1973, Nature 241:210-211) demonstrated that the intestinal microflora present in some adult chickens (i.e. the cecal microflora) interferes with colonization by salmonellae of newly hatched chicks. The application of this concept, known as the Nurmi concept or competitive exclusion, has been successfully tested in some laboratories and is also used commercially (Watkins and Miller, 1983, Poultry Sci. 62:1772-1779; Wierup et al., 1988, Poultry Sci. 67:1026-1033; Impey et al., 1982, J. Hyg. Camb. 89:749; Snoeyembos et al., 1978, Avian Dis. 22:273-287). There are many problems associated with this method, in particular, a lack of adequate selective isolation and characterization techniques to study and consistently obtain cecal flora preparations (Bailey, 1988, Poultry Sci. 67:928-932; Mead and Impey, 1986, J. Bacteriol. Symp. Suppl. 675-755; Soerjadi et al., 1981, Avian Dis. 25:1027-1033.
Mannose and lactose were shown to significantly reduce Salmonella typhimurium adherence to the ceca of chicks (Oyofo et al., 1989, Avian Dis. 33:531-534). The inhibitory effect of these sugars was believed to take place by blocking the receptor sites on the gut epithelium and on the microorganism pili. It has been shown that providing dietary lactose together with cecal flora
contents to broiler chickens reduced the occurrence of Salmonella (Corrier et al., 1990, Avian Dis. (in press); Hinton et al., 1990, Avian Dis. (in press); Oyofo et al., 1989) . Historically, Lactobacillus administration (i.e., inclusion of viable cells in the feed) to animals has not yielded consistent benefits. There are many reasons for this including, for example, using Lactobacillus species or strains unadapted to or unsuitable for the animal being treated, or using conditions which do not produce a colonization of the Lactobacillus within the GI tract.
The object of this invention is to provide a food or feed additive formulation and method comprising isolated and identified pure cultures of Lactobacillus reuteri and/or other Lactobacillus species together with a sugar source such as lactose, using whey as a source for this sugar.
Lactobacillus reuteri was previously found to be recoverable from the stools of piglets after the piglets had been fed large quantities of the cells (co-pending application) . It was hypothesized in the co-pending application that such cells could be used, possibly in conjunction with glycerol, as a growth and health aid for these animals. Evidence has been obtained (and presented below) that L.reuteri may be administered to poultry as a means of competitively excluding salmonellae.
It is an object of this invention to provide a formulation that may be used as a food or food additive
ixture that utilizes pure cultures of one or more of certain Lactobacillus species in addition to a sugar source.
It is a further object of the invention to provide a formulation that results in rapid weight gain for growing animals.
It is a further object of the invention to provide a formulation that decreases the number of pathogenic microorganisms in the gastrointestinal tract, with the purpose of adding any sugar for at least the purpose of being a source of carbohydrate for the metabolism of the Lactobacillus but not utilized by the animal or the unwanted microorganism(s) .
Other objects and advantages will be more fully apparent from the following disclosure and appended claims.
SUMMARY OF THE INVENTION The invention is for a formulated product that may be used as an animal feed additive and that includes isolated and identified pure culture(s) of naturally occurring gastrointestinalmicroorganisms, for example, Lactobacillus reuteri, L. animalis, and/or L. salivarius. The formulated product also includes a sugar source. The invention also includes a method of feeding the formulation to animals. Preferably the sugar source is whey, when animals which do not metabolize lactose such as chickens are used, because whey contains the sugar lactose and is an easily obtainable and voluminous waste product.
The formulation of the invention when fed to animals provides a means to decrease populations of undesirable gastrointestinal microbes and results in increased weight gain of the animals, especially under the less than optimum growth conditions normally present in commercial livestock environments.
Other aspects and features of the invention will be more fully apparent from the following disclosure and appended claims.
DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS THEREOF The present invention provides a formulation usable as a food or feed additive for animals. In the particular invention, such animals specifically include all poultry and mammals, including human beings. The formulation for a particular animal comprises one or more pure cultures of a Lactobacillus species naturally occurring in the gastrointestinal tract of that animal and a source of a sugar that is metabolizable by the Lactobacillus species but not to any great extent by the animal. Thus, the formulation of the invention comprises:
(a) a bacterial culture comprising at least one live pure culture of a Lactobacillus species which occurs naturally in a particular animal group; and
(b) a source of sugar metabolizable by the Lactobacillus species in the bacterial culture
but not metabolizable by the animals in the grou . By the term "group" is meant animals of a particular species or group of species which share in common a tendency to have a similar gastrointestinal Lactobacillus flora and a similar inability to metabolize a sugar which is metabolizable by the Lactobacillus flora. As discussed below, the formulation discussed in detail herein has been devised for poultry but is adaptable to other animals, and includes a source of lactose which is not metabolizable by poultry.
In the preferred embodiment, the formulation comprises live, pure cultures of at least one of Lactobacillus reuteri, L. animalis and L. salivarius, and a sugar source. The preferred sugar source is whey, because it is inexpensive and easily available, and because it contains lactose, a good source of carbon and energy for growth of the added microorganisms. An additional advantage of using a lactose source for feeding poultry or other birds is that birds do not utilize this sugar, and it is therefore readily available for the added microorganisms. Preferably, powdered whey is utilized as the lactose source to minimize shipping costs and spoilage prior to formulation of the additive. The preferred method of formulating the additive is as follows. L.reuteri. L.animalis and L.salivarius are grown individually in a variety of appropriate media used for lactobacilli. Lactose or maltose are the preferred sources
of energy so that the cells are capable of rapid metabolism of the carbohydrates which may be present in the formulation or in the animals' food. The cells used for the preparation of the additive may be freshly harvested, frozen, lyophilized or suspended in oil or a specifically formulated diluent such as an aqueous solution. Commercially available whey powder or whey concentrate is used to formulate the additive. Although the cells and whey may be fed separately, the are preferably mixed together with or without other ingredients (e.g. corn, soybean meal, wheat, etc.). The mixture may be of a variety of microbe and whey mixtures, for example a solid and a solid (e.g. fine powder with granulated whey, etc.), a liquid and a solid (cell suspension and whey), a solid and a liquid (lyophilized cells and. a liquid whey concentrate) or a liquid and a liquid (liquid cell suspension and a liquid whey concentrate) . The additive final presentation of the mixture could be as a powder, granules, or pellets or liquid. Animals may be fed the additive in a variety of ways: for example, (1) the additive may be combined with dry feed during feed milling or when the feed is delivered to the animals; (2) the additive may be sprinkled on the food as a powder; or (3) the additive may be mixed in the drinking water. Preferably, to minimize labor, the additive is mixed with dry feed.
The features and advantages of the present invention will be more clearly understood by reference to the
following examples, which are not to be considered as limiting the invention.
EXAMPLES Example l. Growth of Turkey Poults to be Fed Additive Experimentally
One day old Nicholas turkey torn poults are used in this study. The poults are not toe clipped, desnooded or wing clipped, nor are they given any vaccinations.
The turkeys are placed in animal rooms at the Dearstyne Poultry Research Center, Department of Poultry Science at NCSU's Agricultural Research Service (NCARS). The animal rooms have controlled ambient temperature, day length and thermostatically controlled Petersime brooding batteries (Petersime Incubator Co., Petersime, OH). A normal turkey starter diet, for example as shown in Table 1 with and without whey powder, is used throughout the trial. The amount of whey in the diet allows for a final 2.2% lactose. The trial is twenty days in duration, covering the period from day of hatch to day 12. The turkeys are weighed on Day 0 (at hatch), Day 5, Day 12, Day 15 and Day 20.
turkeys, are the strains which are used. The Lactobacillus strains are grown in LCM medium utilizing lactose or maltose for 24 h at 37°C, harvested by centrifugation, and washed twice with fresh basal medium as previously described (Axelsson et al., 1989, Microbial
Ecol. Health Dis. 2:131-136; Chung et al., 1989, Microbial Ecol. Health Dis. 2:137-144). These cells are mixed into the animal feed at a level of approximately 105 CFU g'1 of feed. This inoculum level has been shown to effectively enhance the population level of this microorganism in the chicken ceca (Casas et al., 1990, in preparation). The number of L♦ reuteri in the feed and in the ceca are monitored as previously described (Chung et al., 1989, Microbiol. 56: 943-948). Appropriate dilutions are plated onto LBS agar and incubated anaerobically (Gas-Pak jars) at 37°C for 48 h. Plates containing about 50 to 200 CFU are overlaid with glycerol agar seeded with L. plantarum indicator cells, reincubated anaerobically for 24 h, and colonies showing growth inhibition zones counted as reute in-producing L.reuteri cells.
S. senf enberσ, isolated from turkeys, resistant to novobiocin and nalidixic acid, was obtained from Evillmar
Poultry Co. (Evillmar, MN) . Inocula for infectious challenge are prepared from cultures grown in BHI Broth (Difco Laboratories, Inc., Detroit, MI) and incubated at
37°C for 24 hours. The cultures are diluted appropriately in sterile 50 mM phosphate buffer, pH 7.0, to obtain challenge inocula containing 106 CFU per ml. Enumeration of these Salmonella is carried out by plating appropriate dilutions on Rembach Salmonella medium (Rembach, 1990,
Appl. Environ. Microbiol. 56:301-303).
Caecal content samples formicrobiological enumeration are prepared from sacrificed birds. Caeca are carefully
removed from the birds and the open end of each is clipped. The exterior of the caecum is alcohol sterilized before transferring its contents to a stomacher bag for mixing and further dilution.
Example 3. Treatment of Poults
Turkey poults of Example 1 are subjected to the following eight treatments with two pens of 15 birds per pen being in each group:
Salmonella senftenberg infected group 1. Control, no whey, no L.reuteri
2. No whey, L.reuteri
3. Whey, no L.reuteri
4. Whey, L.reuteri
L.reuteri, when administered is mixed into the feed. The inoculated feed is changed every two days to guarantee the presence of viable L. reuteri in the feed. Whey is added to the feed, before milling, for a final 5% lactose concentration. Alternatively, L. reuteri and concentrated or dehydrated whey are formed into tablets , or added together in any product in which both components in a liquid or solid form have been previously combined, and the combination added to the feed of the animals.
5. senftenberg (106 CFU per ml) is crop fed by the means of an animal feeding stainless steel needle attached to a hypodermic syringe on day 5 after hatch.
Example 4. Results of Addition of Lactobacillus, Whey and Salmonella
Salmonella senftenberg in feces and caecal contents of poults treated as in Example 3 is shown in Tables 2 and 3, respectively. The effect of L. reuteri and whey on the number of S. senftenberg in feces (droppings) becomes obvious at 72 h after Salmonella challenge. The data indicate a synergistic effect when whey and L. reuteri are added together.
The presence of S. senftenberg in caecal contents is presented in Table 3. The results show that addition of L. reuteri and/or whey, but in particular, the combination of . reuteri and whey, is effective in reducing the presence of S. senf enberg in the ceca of these animals. Thus, whereas 47% of the control ceca tested positive for S. senftenberg, none (0%) of the samples tested positive when fed L. reuteri and whey.
TABLE 2. Log10 CFU of S. senftenberg per g feces 72 h post challenge.
TABLE 3. Percent of cecal samples testing positive for S. senftenberg and L. reuteri 7 days post challenge
1 Positive samples had > 107 CFU/g
2 Positive samples had < 103 CFU/g
Example 5. Growth of Cold Stressed Poults Fed with L. reuteri and Whey
Instead of exposing turkey poults to constant temperature rooms as in Example 1, the temperature in the pens of cold stressed birds is 90 degrees F for 1 hour, then 85 degrees G for 2 hours in an on-off cycling for 48 hours after hatch. The temperature is then set back to normal brooding temperature for the remainder of the experiment, normal brooding temperature being 90 degrees F for the first seven days after hatch, 85 degrees F from day 7 to day 10, and 75 to 80 degrees after day 10.
Turkey poults are subjected to the following four treatments, with eight pens of eight birds per pen being in each treatment group:
1. Control, no whey, no L. reuteri 2. No whey, L. reuteri
3. Whey, no L. reuteri
4. Whey, L. reuteri
Example 6. Results of Growth of Cold Stressed Poults
Relative wights of poults treated as in Example 5 , at 0, 5, 10, 15, and 20 days of age are shown in Table 4. The beneficial effect of whey becomes evident at day 5, while the effect of L. reuteri becomes obvious at days 15 and 20.
TABLE 4. Effect of L. reuteri and whey on body weight of turkey poults.
TREATMENTS RELATIVE WEIGHT (PERCENT) AT
Day 0 Day 5 Day 10 Day 15 Day 20
For percentage conversion, control weights (no whey, no L. reuteri) at each weight day were made equal to 100%.
Example 1. Use of Lactobacillus salivarius and
Lactobacillus animalis L. salivarius subsp. salivarius ATCC type strain No. 11741 and L. animalis ATCC type strain No. 35046 are grown
as in Example 2. Each strain is added individually to feed as in Example 3. The feed is augmented with whey according to Example 3. The feed is used to feed chickens and turkeys to decrease undesirable microbial organisms and improve poultry weight gain.
Example 8. Use of Multiple Lactobacillus Strains
Strains of the three Lactobacillus species discussed in Examples 3 and 8 are each added individually, or as a mixed inoculum to the whey-augmented feed according to Example 3. The feed containing the three strains is used to feed turkeys and chickens.
BEST MODE FOR CARRRYING OUT THE INVENTION
The food or feed additive for animals, such as poultry and mammals, including human beings, comprises one or more pure cultures of a Lactobacillus species naturally occurring in the gastrointestinal tract of that animal and a source of a sugar that is metabolizable by the Lactobacillus species but not to any great extent by the animal. Preferably, the formulation comprises live, pure cultures of at least one of Lactobacillus reuteri. L. animalis and L. salivarius, and a sugar source. The preferred sugar source is whey, particularly for poultry. Whey is inexpensive and easily available, contains lactose, a good source of carbon and energy for growth of the added microorganisms, and is not utilized poultry or other birds and therefore readily available for the added
microorganisms. Preferably, powdered whey is utilized as the lactose source to minimize shipping costs and spoilage prior to formulation of the additive.
The preferred method of formulating the additive is as follows. L.reuteri, L.animalis and L.salivarius are grown individually in a variety of appropriate media used for lactobacill. The cells used for the preparation of the additive may be freshly harvested, frozen, lyophilized or suspended in oil or a specifically formulated diluent such as an aqueous solution. Commercially available whey powder or whey concentrate is used to formulate the additive. The cells and whey are preferably mixed together with or without other ingredients (e.g. corn, soybean meal, wheat, etc.). Animals are preferably fed the additive as a mixture with dry feed.
INDUSTRIAL APPLICABILITY The invented formulation may be used as a food or food additive mixture for animals grown commericially, such as poultry. It provides a product that results in rapid weight gain for growing animals, and decreases the number of pathogenic microorganisms in the gastrointestinal tract, thereby resulting in increased productivity and decreased animal mortality.
While the invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments
are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the invention.
Claims
1. A formulation for oral administration to an animal of a particular group, comprising: (a) a bacterial culture comprising at least one live pure culture of at least one Lactobacillus species which occurs naturally in a particular animal group; and (b) a source of sugar metabolizable by the Lactobacillus species in the bacterial culture but not metabolizable by the animals in the group.
2. A formulation for oral administration according to Claim 1, comprising a Lactobacillus culture selected from the group consisting of L.reuteri, L.salivarius and L.animalis, and the animals are poultry.
3. A formulation for oral administration according to Claim 1, wherein the source of sugar comprises whey.
4. A formulation for oral administration according to Claim 1, wherein the Lactobacillus culture is selected from the group consisting of L.reuteri, L.salivarius and L.animalis, and the source of sugar is whey.
5. A formulation for oral administration according to Claim 4, further comprising glycerol.
6. A formulation for oral administration according to Claim 1, wherein pure cultures of L.reuteri. L.salivarius and L.animalis are used, and the sugar is lactose.
7. A formulation for oral administration according to Claim 6, wherein the source of lactose is whey.
8. A formulation for oral administration to animals, comprising: (a) a bacterial culture consisting of at least one live, pure culture of Lactobacillus: and (b) a source of sugar.
9. A formulation for oral administration according to Claim 8, comprising a Lactobacillus culture selected from the group consisting of L.reuteri. L.salivarius and L.animalis. and the animals are poultry.
10. A formulation for oral administration according to Claim 8, wherein the source of sugar comprises whey.
11. A formulation for oral administration according to Claim 8, wherein the Lactobacillus culture is selected from the group consisting of L.reuteri, L.salivarius and L.animalis. and the source of sugar is whey.
12. A formulation for oral administration according to Claim 11, further comprising glycerol.
13. A formulation for oral administration according to Claim 8, wherein pure cultures of L.reuteri. L.salivarius and L.animalis are used, and the sugar is lactose.
14. A formulation for oral administration according to Claim 13, wherein the source of lactose is whey.
15. A method of decreasing numbers of undesirable microbes in an animal's gastrointestinal tract, comprising: (a) obtaining at least one pure culture of Lactobacillus cells;
(b) obtaining a source of sugar; and
(c) administering the Lactobacillus cells and the sugar orally to the animal.
16. A method of decreasing numbers of undesirable microbes in gastrointestinal tracts of animals, comprising:
(a) obtaining at least one pure culture of Lactobacillus cells;
(b) obtaining a source of sugar metabolizable by the Lactobacillus cells and not to a significant extent by the animals or the undesirable microbes; and
(c) administering the Lactobacillus cells and the sugar orally to the animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1991/003796 WO1993002558A1 (en) | 1991-08-01 | 1991-08-01 | Method and formulation for reducing microbial populations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1991/003796 WO1993002558A1 (en) | 1991-08-01 | 1991-08-01 | Method and formulation for reducing microbial populations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993002558A1 true WO1993002558A1 (en) | 1993-02-18 |
Family
ID=22225569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/003796 WO1993002558A1 (en) | 1991-08-01 | 1991-08-01 | Method and formulation for reducing microbial populations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993002558A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5531681A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US5533973A (en) * | 1995-01-13 | 1996-07-09 | Abbott Laboratories | Alteration of nutritional product during enteral tube feeding |
WO1999043370A1 (en) | 1998-02-27 | 1999-09-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US6080132A (en) * | 1998-02-27 | 2000-06-27 | Abbott Laboratories | Apparatus for altering characteristics of a fluid |
US6251432B1 (en) | 1999-07-01 | 2001-06-26 | Abbott Laboratories | Sustained release dosage form unit having latex coating and method of making the same |
US6309373B1 (en) | 1998-08-12 | 2001-10-30 | Abbott Laboratories | Apparatus for altering the characteristics of a fluid |
ES2292322A1 (en) * | 2005-10-20 | 2008-03-01 | Institut De Recerca I Tecnologia Agroalimentaries | New bacterial strains pure biological cultures for preparing compositions that eliminate colonization by pathogenic strain of species of Salmonella of gastrointestinal tract in domestic birds, are formed of two bacterial strains |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US8519008B2 (en) | 2003-01-22 | 2013-08-27 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3984575A (en) * | 1974-02-06 | 1976-10-05 | Microlife Technics, Inc. | Bacterial compositions for changing the digestive system bacteria in animals |
US3988440A (en) * | 1973-10-11 | 1976-10-26 | Dso "Pharmachim" | Remedy for treating gastritis, gastric and duodenal ulcers |
US4314995A (en) * | 1976-02-23 | 1982-02-09 | Seikenkai | Pharmaceutical lactobacillus preparations |
US4518696A (en) * | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
US4591499A (en) * | 1984-01-20 | 1986-05-27 | J. B. Lima, Inc. | Method for treatment and prevention of mastitis |
JPS62130680A (en) * | 1985-12-03 | 1987-06-12 | Karupisu Shokuhin Kogyo Kk | Novel lactic acid bacteria |
US4689226A (en) * | 1980-01-11 | 1987-08-25 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
US4980164A (en) * | 1986-10-02 | 1990-12-25 | Bio Techniques Laboratories, Inc. | Strains of lactobacillus for enhancing feed conversion efficiency |
-
1991
- 1991-08-01 WO PCT/US1991/003796 patent/WO1993002558A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3988440A (en) * | 1973-10-11 | 1976-10-26 | Dso "Pharmachim" | Remedy for treating gastritis, gastric and duodenal ulcers |
US3984575A (en) * | 1974-02-06 | 1976-10-05 | Microlife Technics, Inc. | Bacterial compositions for changing the digestive system bacteria in animals |
US4314995A (en) * | 1976-02-23 | 1982-02-09 | Seikenkai | Pharmaceutical lactobacillus preparations |
US4689226A (en) * | 1980-01-11 | 1987-08-25 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
US4518696A (en) * | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
US4591499A (en) * | 1984-01-20 | 1986-05-27 | J. B. Lima, Inc. | Method for treatment and prevention of mastitis |
JPS62130680A (en) * | 1985-12-03 | 1987-06-12 | Karupisu Shokuhin Kogyo Kk | Novel lactic acid bacteria |
US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
US4980164A (en) * | 1986-10-02 | 1990-12-25 | Bio Techniques Laboratories, Inc. | Strains of lactobacillus for enhancing feed conversion efficiency |
Non-Patent Citations (3)
Title |
---|
DOBROGOSZ et al., "Regulatory and Protective Role of the Normal Microflora", published 1989, see pages 283-292. * |
MICROBIAL ECOLOGY IN HEALTH AND SCIENCE, Volume 2, issued 1989, CHUNG et al., "In Vitro Studies on Reuterin Synthesis by Lactobacillus Reuteri", pages 137-144. * |
POULTRY SCIENCE, Volume 70, Supplement 1, PARKHORST et al., issued 1991, "Lactobacillus Reuteri and Dietary Whey Effect on Twenty Day Body Weights of Turkey Poults Subjected to Either Cold or Low Protein Stress", p. 1-7. * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5531681A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US5533973A (en) * | 1995-01-13 | 1996-07-09 | Abbott Laboratories | Alteration of nutritional product during enteral tube feeding |
WO1996021480A1 (en) * | 1995-01-13 | 1996-07-18 | Abbott Laboratories | Apparatus for altering composition of nutritional product |
US5738651A (en) * | 1995-01-13 | 1998-04-14 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US5755688A (en) * | 1995-01-13 | 1998-05-26 | Abbott Laboratories | Alteration of nutritional product during enteral tube feeding |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
WO1999043370A1 (en) | 1998-02-27 | 1999-09-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US6080132A (en) * | 1998-02-27 | 2000-06-27 | Abbott Laboratories | Apparatus for altering characteristics of a fluid |
US6309373B1 (en) | 1998-08-12 | 2001-10-30 | Abbott Laboratories | Apparatus for altering the characteristics of a fluid |
US6620434B2 (en) | 1999-07-01 | 2003-09-16 | Abbott Laboratories | Sustained release dosage form unit having latex coating and method of making the same |
US6251432B1 (en) | 1999-07-01 | 2001-06-26 | Abbott Laboratories | Sustained release dosage form unit having latex coating and method of making the same |
US11452303B2 (en) | 2003-01-22 | 2022-09-27 | Purina Animal Nutrition Llc | Methods for feeding sows and for improving the health of young piglets |
US10980250B2 (en) | 2003-01-22 | 2021-04-20 | Purina Animal Nutrition Llc | Methods for feeding sows and for improving the health of young piglets |
US10172376B2 (en) | 2003-01-22 | 2019-01-08 | Purina Animal Nutrition Llc | Methods for feeding sows and for improving the health of young piglets |
US9433232B2 (en) | 2003-01-22 | 2016-09-06 | Purina Animal Nutrition Llc | Methods for feeding sows and for improving the health of young piglets |
US9078457B2 (en) | 2003-01-22 | 2015-07-14 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
US8519008B2 (en) | 2003-01-22 | 2013-08-27 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
US9580680B2 (en) | 2003-12-19 | 2017-02-28 | Mars, Incorporated | Canine probiotic bifidobacterium pseudolongum |
US8840880B2 (en) | 2003-12-19 | 2014-09-23 | The Iams Company | Canine probiotic bifidobacteria globosum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
US8900568B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
US9821015B2 (en) | 2003-12-19 | 2017-11-21 | Mars, Incorporated | Methods of use of probiotic bifidobacteria for companion animals |
US8802158B2 (en) | 2003-12-19 | 2014-08-12 | The Iams Company | Methods of use of probiotic Lactobacilli for companion animals |
US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
US9427000B2 (en) | 2005-05-31 | 2016-08-30 | Mars, Incorporated | Feline probiotic lactobacilli composition and methods |
US9404162B2 (en) | 2005-05-31 | 2016-08-02 | Mars, Incorporated | Feline probiotic bifidobacteria and methods |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
ES2292322A1 (en) * | 2005-10-20 | 2008-03-01 | Institut De Recerca I Tecnologia Agroalimentaries | New bacterial strains pure biological cultures for preparing compositions that eliminate colonization by pathogenic strain of species of Salmonella of gastrointestinal tract in domestic birds, are formed of two bacterial strains |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10709156B2 (en) | 2008-07-07 | 2020-07-14 | Mars, Incorporated | Pet supplement and methods of making |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jadhav et al. | Probiotics in broiler poultry feeds: A review | |
JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
US5951977A (en) | Competitive exclusion culture for swine | |
CN101262779B (en) | Probiotic health or fitness promoting foodstuff, feed, and/or drinking water additive and use thereof | |
Brashears et al. | Lactic acid bacteria and their uses in animal feeding to improve food safety | |
WO1993002558A1 (en) | Method and formulation for reducing microbial populations | |
EP0987957A1 (en) | Method for administering viable microorganism composition for poultry | |
WO2007058027A1 (en) | Harmful bacterium control agent containing bacillus thuringiensis | |
Deniz et al. | Effects of probiotic (Bacillus subtilis DSM 17299) supplementation on the caecal microflora and performance in broiler chickens | |
Husmaini et al. | Growth and survival of lactic acid bacteria isolated from by-product of virgin coconut oil as probiotic candidate for poultry | |
CA2100774C (en) | Feed additive and method | |
Wang et al. | Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs | |
US20140037605A1 (en) | Anticoccidial composition | |
KR20090078065A (en) | Antimicrobial-enhanced Lactic Acid Bacteria Preparation and its Manufacturing Method | |
JP2006169197A (en) | Antimicrobial agent for livestock and composition for feed | |
Hidayat et al. | Total of Escherichia coli excreta broiler given Enterococcus sp. as probiotics candidate of poultry | |
WO2012063345A1 (en) | Immunopotentiating agent, immunopotentiating composition containing same, and immunopotentiating method | |
WO1995004539A1 (en) | Immunopotentiator and method of immunopotentiating animal with the same | |
US8673290B2 (en) | Sporulation-deficient B. texasporus cells and methods for efficient and cost-effective inactivation and use thereof | |
FI112374B (en) | Procedure for feeding live microorganisms to poultry in ovo | |
RU2779603C1 (en) | Feed additive with phytoprobiotic activity for the prevention and treatment of poultry diseases | |
Oliveira et al. | In Vitro Selection and In Vivo Trial of Lactobacillus strains for use a potential probiotics for laying hens | |
Ivanov | Laboratory study to determine the effect of a probiotic mixture on chicken-broiler | |
Oliveira et al. | In vitroSelection and In vivoTrial of Lactobacillus Strains for Use a Potential Probiotics for Laying | |
F Farag et al. | The Effect of Bacillus subtilis on The Bacterial Content in Rabbits Caeci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA FI JP KP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |